Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson's Disease (STIMO-PARK)

Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson's Disease

STIMO-PARKINSON: Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson's Disease

The purpose of the STIMO-PARKINSON study is to evaluate the safety and preliminary efficacy of Targeted Epidural Spinal Stimulation (TESS) system to induce modulation in leg muscle recruitment in patients with advanced Parkinson's disease, and its capacity to improve key gait and balance deficits when employed in the context of a rehabilitation process of 3 to 5 months.

The study intervention consists of 7 phases preceded by pre-screening: enrolment and eligibility baseline surgery main phase of the study home-use end of main study phase (optional and conditional): 3 years follow-up At baseline, general information and Parkinson related medical history are collected. Clinical evaluations are also completed without and with current therapy, (i.e. NO(MED+DBS), and MED+DBS conditions). Finally, quality of life questionnaires are collected for the patient as well as expectations questionnaires for the physiotherapists involved in the study. The main phase of the study consists of: Stimulation configuration sessions during which TESS protocols will be setup and optimized. This procedure aims to configure the spatial and temporal parameters of TESS that will recruit specific muscle groups. Specific TESS protocols will be configured for various motor tasks which will be used during the rehabilitation phase and clinical evaluations. TESS-supported rehabilitation sessions during which patients will undergo an in-clinic rehabilitation training regime supported by TESS. Evaluation sessions during which four clinical evaluation sessions will take place focusing on assessment of locomotion, balance and PD related deficits. The tests will be done when patients are: (i) in NO(MED+DBS) condition (without any therapy, i.e. without medication and DBS OFF) (ii) in MED+DBS condition (the patient's standard therapeutical condition, i.e. usual medication dose and DBS ON) (iii) in TESS+MED condition (usual medication dose, TESS ON, DBS OFF) (iv) in TESS+MED+DBS condition (usual medication dose, TESS ON, DBS ON) Participants are allowed to use the investigational system independently if deemed safe and beneficial as assessed by the Principal Investigator (Home-Use Phase). One year after patient enrolment, the patient will come for follow up visits where he will again perform an evaluation session for each therapy condition as described above, to evaluate the long-term evolution. If the therapy has been safe and beneficial, they can extend their study participation by entering the Follow-Up period of 3 years.

Patient will be asked to come to the hospital for three types of patient sessions: Stimulation configuration sessions: TESS protocols will be setup and optimized during this phase. Duration: minimum 4 sessions over 2 weeks, maximum 20 sessions over a month. In addition, some sessions at a free frequency as needed during rehabilitation will be programed (maximum once a week). TESS-supported rehabilitation sessions: Patients will undergo an in-clinic rehabilitation training regime supported by TESS. Duration: 24 sessions spread over minimum three months and maximum five months Pre- and post-rehabilitation evaluation sessions: four clinical evaluation sessions will take place focusing on assessment of locomotion, balance and PD related deficits.

The intervention involves the implantation of: a neurostimulator: the Activa® RC from Medtronic a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic

Occurence of all SAEs and AEs deemed or related to study procedure or to the study investigational system

Evaluate the safety of TESS at supporting locomotor rehabilitation in patients with Parkinson's Disease

EMG measurements of muscle recruitment in response to stimulation of increasing amplitudes for different contact configurations

Assess the preliminary efficacy outcome of TESS to induce modulations in muscle recruitment selectivity by measuring the EMG response to iterative stimulation pulses of increasing amplitude for different contact configurations

Assess the preliminary efficacy of TESS on motor performance through changes in single joint leg muscle strength and fatigue

Measure the time the patient can maintain a certain percentage of his MVC measured in the MED+DBS condition. This is used to assess the preliminary efficacy of TESS on motor performance through changes in single joint leg muscle strength and fatigue

Assess the preliminary efficacy of TESS on motor performance through changes in gait speed and endurance

Assess the preliminary efficacy of TESS on motor performance through changes in gait speed and endurance

Assess the preliminary efficacy of TESS for alleviating deficits specific to PD related to freezing of gait (FOG)

Assess the preliminary efficacy of TESS for alleviating deficits specific to PD related to posture using motion sensors acquisition system

Assess the preliminary efficacy of TESS for alleviating deficits specific to PD related to motor and non-motor functions. Higher scores indicate greater impact of Parkinson's disease symptoms

Assess changes in brain activity patterns induced by TESS-supported physical training to get insight into the effects of TESS on brain dynamics. This will be done in the four therapy conditions for rest, for single-joint leg tasks and, if results are encouraging, for gait

Evaluate the effect of TESS-supported rehabilitation on quality of life of patients through the Parkinson's Disease Questionnaire (PDQ-39). The score ranges from 0 to 100, lower scores reflect better quality of life

Evaluate the effect of TESS-supported rehabilitation on quality of life of patients through the Activities-specific Balance Confidence Scale (ABC-Q). The score ranges from 0% to 100%, higher score reflects higher level of physical functioning

Evaluate the effect of TESS-supported rehabilitation on quality of life of patients through the Freezing of Gait Questionnaire (FOG-Q). The score ranges from 0 to 24, higher scores correspond to more severe FOG

Evaluate the effect of TESS-supported rehabilitation on quality of life of patients through King's Parkinson's disease pain scale. The score ranges from 0 to 168, higher scores correspond to higher pain.

Obtain information concerning the perceived efficacy of TESS-supported rehabilitation for Parkinson's patients and whether they would recommend tis new therapy for general clinical practice

Inclusion Criteria: Idiopathic Parkinson's disease with III-IV Hoehn-Yahr stage, exhibiting severe gait difficulties and postural instability With Medtronic DBS implant and receiving medication for Parkinson's disease Aged 18 to 80 years Stable medical, physical and psychological condition as considered by the Investigators in accordance with treating physician and treating neurologist. Must agree to comply in good faith with all conditions of the study and to attend all required study training and visit Must provide and sign the study's Informed Consent prior to any study-related procedures Exclusion Criteria: Severe or chronic medical disorder pre-existing PD diagnosis affecting rehabilitation Active oncological disease requiring heavy treatments and frequent MRI controls Having an implanted device that is active (e.g., pacemaker, implantable cardiac defibrillator) whose interference with the investigational system's neurostimulator (Activa RC) is not confirmed safe by the CE-mark of the device, or having an indication that might lead to implantation of such device Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia as considered by the Investigators in accordance with treating physician and treating neurologist Hematological disorders with an increased risk of hemorrhagic event during surgical interventions Life expectancy of less than 12 months Pregnant or breast feeding Participation in another interventional study

Strauss I, Kalia SK, Lozano AM. Where are we with surgical therapies for Parkinson's disease? Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S187-91. doi: 10.1016/S1353-8020(13)70044-0.

Courtine G, Bloch J. Defining ecological strategies in neuroprosthetics. Neuron. 2015 Apr 8;86(1):29-33. doi: 10.1016/j.neuron.2015.02.039.

Courtine G, Gerasimenko Y, van den Brand R, Yew A, Musienko P, Zhong H, Song B, Ao Y, Ichiyama RM, Lavrov I, Roy RR, Sofroniew MV, Edgerton VR. Transformation of nonfunctional spinal circuits into functional states after the loss of brain input. Nat Neurosci. 2009 Oct;12(10):1333-42. doi: 10.1038/nn.2401. Epub 2009 Sep 20.

Capogrosso M, Milekovic T, Borton D, Wagner F, Moraud EM, Mignardot JB, Buse N, Gandar J, Barraud Q, Xing D, Rey E, Duis S, Jianzhong Y, Ko WK, Li Q, Detemple P, Denison T, Micera S, Bezard E, Bloch J, Courtine G. A brain-spine interface alleviating gait deficits after spinal cord injury in primates. Nature. 2016 Nov 10;539(7628):284-288. doi: 10.1038/nature20118.

Fuentes R, Petersson P, Siesser WB, Caron MG, Nicolelis MA. Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science. 2009 Mar 20;323(5921):1578-82. doi: 10.1126/science.1164901.

Yadav AP, Nicolelis MAL. Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease. Mov Disord. 2017 Jun;32(6):820-832. doi: 10.1002/mds.27033. Epub 2017 May 12.

Santana MB, Halje P, Simplicio H, Richter U, Freire MAM, Petersson P, Fuentes R, Nicolelis MAL. Spinal cord stimulation alleviates motor deficits in a primate model of Parkinson disease. Neuron. 2014 Nov 19;84(4):716-722. doi: 10.1016/j.neuron.2014.08.061. Epub 2014 Oct 30.

Cai Y, Reddy RD, Varshney V, Chakravarthy KV. Spinal cord stimulation in Parkinson's disease: a review of the preclinical and clinical data and future prospects. Bioelectron Med. 2020 Mar 16;6:5. doi: 10.1186/s42234-020-00041-9. eCollection 2020.

Prasad S, Aguirre-Padilla DH, Poon YY, Kalsi-Ryan S, Lozano AM, Fasano A. Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A 1-Year Prospective Trial. Mov Disord. 2020 Jun;35(6):1082-1083. doi: 10.1002/mds.28065. Epub 2020 Apr 20. No abstract available.

Cury RG, Carra RB, Capato TTC, Teixeira MJ, Barbosa ER. Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure? Mov Disord. 2020 Oct;35(10):1882-1883. doi: 10.1002/mds.28271. No abstract available.